Download Pfizer Oncology Data Presentations at the 2016 European Society

Pfizer Oncology Data Presentations at the 2016 European Society for Medical Oncology (ESMO)
Congress
The embargo on most data will lift on Wednesday, September 28, at 6:00 a.m. ET unless otherwise noted.
At the 2016 European Society for Medical Oncology (ESMO) Congress, multiple Pfizer-sponsored abstracts will be
presented highlighting clinical progress for eight Pfizer Oncology assets. The presentations span multiple tumor types and
mechanisms of action.
Avelumab:
(Abstract 775PD) Phase 1b Dose-Finding Study of Avelumab (ANTI-PD-L1) + Axitinib in Treatment-Naïve Patients
with Advanced Renal Cell Carcinoma. Larkin, J. Sunday, October 9. Session Type: Poster Discussion. Presentation
Time: 16:30 – 17:30 CEST. Location: Athens.
(Abstract 777PD) Avelumab (MSB0010718C; anti-PD-L1) in Patients with Metastatic Urothelial Carcinoma
Progressed After Platinum-Based Therapy or Platinum Ineligible. Patel, M. Sunday, October 9. Session Type: Poster
Discussion. Presentation Time: 16:30 – 17:30 CEST. Location: Athens.
(Abstract 1154P) Evaluation of Real World Treatment Outcomes in Patients with Metastatic Merkel Cell Carcinoma
(MCC) Following Second Line Chemotherapy. Becker, J. Sunday, October 9. Session Type: Poster Display. Display
Time: 13:00 – 14:00 CEST. Location: Hall E.
(Abstract 842TiP) A Multicentre, International, Randomised, Open-Label Phase 3 Trial of Avelumab + Best
Supportive Care (BSC) vs BSC Alone as Maintenance Therapy After First-Line Platinum-Based Chemotherapy in
Patients with Advanced Urothelial Cancer (JAVELIN Bladder 100). Powles, T. Sunday, October 9. Session Type:
Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
(Abstract 844TiP) Phase 3 Study of Avelumab in Combination with Axitinib Versus Sunitinib as First-Line
Treatment for Patients with Advanced Renal Cell Carcinoma (aRCC). Motzer, R. Sunday, October 9. Session Type:
Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
Axitinib:
(Abstract 773PD) Axitinib in Combination with Pembrolizumab in Patients (pts) with Advanced Renal Cell
Carcinoma (aRCC): Preliminary Safety and Efficacy Results. Atkins, M. Sunday, October 9. Session Type: Poster
Discussion. Presentation Time: 16:30 – 17:30 CEST. Location: Athens.
(Abstract 825P) Long-Term Duration of Axitinib Treatment in Advanced Renal Cell Carcinoma. Rini, B. Sunday,
October 9. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
Crizotinib:
(Abstract 1206PD) Crizotinib in Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC): Updated
Results from PROFILE 1001. Shaw, A. Sunday, October 9. Session Type: Poster Discussion. Presentation Time: 14:45 –
16:15 CEST. Location: Oslo.
1
(Abstract 1291TiP) Phase 1b Study of Crizotinib in Combination with Pembrolizumab in Patients (pts) with
Untreated ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC). Vizcarrondo, F. Saturday, October 8.
Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
Palbociclib:
(Abstract LBA15) Biomarker Analyses from the Phase 3 PALOMA-2 Trial of Palbociclib (P) with Letrozole (L)
Compared with Placebo (PLB) Plus L in Postmenopausal Women with ER+/HER2- Advanced Breast
Cancer (ABC). Finn, R. Saturday, October 8. Session Type: Proffered Paper. Presentation Time: 11:00 – 12:30 CEST.
Location: Vienna. (Embargoed until Saturday, October 8 at 8:15 CEST)
(Abstract 225PD) Impact of Palbociclib Plus Letrozole on Health Related Quality of Life (HRQOL) Compared with
Letrozole Alone in Treatment Naïve Postmenopausal Patients with ER+ HER2- Metastatic Breast Cancer (MBC):
Results from PALOMA-2. Rugo, H. Sunday, October 9. Session Type: Poster Discussion. Presentation Time: 16:30 –
17:30 CEST. Location: Brussels.
(Abstract 260P) Impact of Palbociclib Plus Fulvestrant on Patient Reported General Health Status Compared with
Fulvestrant Alone in HR+, HER2- Metastatic Breast Cancer. Loibl, S. Monday, October 10. Session Type: Poster
Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
(Abstract 283P) Satisfaction with Cancer Treatments in HR+/HER2- Metastatic Breast Cancer Patients in a Real
World Setting. De Courcy, J. Monday, October 10. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST.
Location: Hall E.
(Abstract 284P) Patient Reported Pain Severity and Interference in HR+/HER2- Advanced/Metastatic Breast
Cancer in Real World Settings. Wood, R. Monday, October 10. Session Type: Poster Display. Display Time: 13:00 –
14:00 CEST. Location: Hall E.
Sunitinib:
(Abstract LBA11_PR) Phase III Trial of Sunitinib (SU) vs Placebo (PBO) as Adjuvant Treatment for High-Risk
Renal Cell Carcinoma (RCC) After Nephrectomy (S-TRAC). Ravaud, A. Monday, October 10. Session Type:
Presidential Symposium. Presentation Time: 16:30 – 18:10. Location: Copenhagen. (Embargoed until Monday, October
10 at 8:15 CEST)
(Abstract 821P) Tolerability Associated with Sunitinib (SU) 2-Week on and 1-Week off Schedule (2/1 Schedule)
Compared with its Standard Schedule in Metastatic RCC (mRCC): Meta-Analysis. Kang, H. Sunday, October 9.
Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
Early Pipeline Assets
OX40 mAB (PF-8600):
2
(Abstract 1053PD) A First-in-Human (FIH) Study of PF-04518600 (PF-8600) OX40 Agonist in Adult Patients (pts)
with Select Advanced Malignancies. Diab, A. Monday, October 10. Session Type: Poster Discussion. Presentation
Time: 9:30 – 10:30 CEST. Location: Berlin.
PTK7 ADC (PF-7020):
(Abstract LBA35) A Phase 1 Study of PF-06647020, an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine
Kinase 7 (PTK7), in Patients with Advanced Solid Tumors Including Platinum Resistant Ovarian Cancer
(OVCA). Sachdev, J. Saturday, October 8. Session Type: Poster Discussion. Presentation Time: 9:30 – 10:30 CEST.
Location: Bern. (Embargoed until Saturday, October 8 at 8:15 CEST)
Biosimilars
PF-05280586:
(Abstract 935P) Development of PF-05280586, a Potential Biosimilar to Rituximab. Jacobs, I. Saturday, October 8.
Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
(Abstract 946TiP) A Randomized Comparative Study of PF-05280586 (a Potential Biosimilar) vs Rituximab for
Patients with CD20+, Low Tumor Burden, Follicular Lymphoma. Jacobs, I. Saturday, October 8. Session Type: Poster
Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.
###
3